Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Fineline Cube Dec 31, 2025
Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Fineline Cube Dec 31, 2025
Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Fineline Cube Dec 31, 2025
Company Deals

Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline

Fineline Cube Dec 31, 2025
Company Deals

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

Fineline Cube Dec 30, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Fineline Cube Dec 31, 2025
Company Drug

Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy

Fineline Cube Dec 31, 2025
Company Medical Device

Lifetech Scientific’s PDA Occluder Gains NMPA Innovative Device Review Status

Fineline Cube Aug 22, 2025

On August 22, 2025, China-based Lifetech Scientific Corporation (HKG: 1302) announced that its nitinol patent...

Company Deals

Bio-Thera Inks EUR 136m Deal with STADA for BAT1806 Commercialization

Fineline Cube Aug 21, 2025

On August 21, 2025, Bio-Thera Solutions, Ltd. (SHA: 688177) announced a license and commercialization agreement...

Company Deals

3D Medicines and CATUG Biotech Forge Strategic Alliance in mRNA-LNP Innovation

Fineline Cube Aug 21, 2025

China-based 3D Medicines (HKG: 1244) has entered into a strategic cooperation framework agreement with CATUG Biotechnology....

Company Drug

Bio-Thera Adjusts BAT3306 Clinical Study to Meet Regulatory Standards

Fineline Cube Aug 21, 2025

On August 21, 2025, China-based Bio-Thera Solutions, Ltd. (SHA: 688177) announced a strategic adjustment to...

Company Drug

Novartis’ Atrasentan Approved in China for IgAN Proteinuria Reduction

Fineline Cube Aug 21, 2025

Switzerland-based Novartis (NYSE: NVS) has received approval from China’s National Medical Products Administration (NMPA) for...

Company Drug

Suzhou Zelgen’s ZG005 and Gecacitinib Win NMPA Approval for Advanced Solid Tumors

Fineline Cube Aug 21, 2025

On August 21, 2025, Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266), a China-based company, announced...

Others

Minova’s MI078 Shows Promising Results in Postpartum Depression Trial

Fineline Cube Aug 21, 2025

Nanjing-based Minova Pharmaceuticals Co., Ltd. has announced positive results from a Phase 2 clinical trial...

Company Deals

Abbisko’s ABSK043 Gains IND Approval for KRAS G12C NSCLC in Partnership with Allist

Fineline Cube Aug 21, 2025

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that the Center for Drug Evaluation...

Company Drug

Sino Biopharma’s Zongertinib Receives Second Breakthrough Designation for NSCLC

Fineline Cube Aug 21, 2025

On August 20, 2025, Sino Biopharmaceutical Limited (HKG: 1177) announced that its selective HER2 tyrosine...

Company Deals Medical Device

Haohai Biotech Terminates OK Lens Distribution Deal with Brighten Optix Amid Carl Zeiss Acquisition

Fineline Cube Aug 21, 2025

Shanghai Haohai Biological Technology Co., Ltd. (HKG: 6826, SHA: 688366) announced the termination of its...

Company Deals

Nanjing Zenshine Pharma Partners with Cigalah Medpharm to Advance Sebaloxavir Marboxil in MENA

Fineline Cube Aug 21, 2025

On August 21, 2025, Nanjing Zenshine Pharmaceuticals Co., Ltd, a China-based developer of small molecule...

Policy / Regulatory

China Releases Draft Guidelines for Single-Arm Oncology Trials to Support Drug Approvals

Fineline Cube Aug 21, 2025

On August 20, 2025, the Center for Drug Evaluation (CDE) of the National Medical Products...

Company

Ascentage Pharma Reports H1 2025 Financial Results, Shows Strong Growth in Olverembatinib Sales

Fineline Cube Aug 21, 2025

China-based Ascentage Pharma (NASDAQ: AAPG; HKG: 6855) reported its financial results for the first half...

Company Drug

Chongqing Genrix Bio Pharmaceutical’s GR1802 Injection Receives NMPA Approval for Seasonal Allergic Rhinitis in Adolescents

Fineline Cube Aug 20, 2025

China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) has announced that its investigational product, GR1802...

Company Deals

Santhera Pharmaceuticals Signs Exclusive Agreement with Uniphar for AGAMREE Distribution in Middle East

Fineline Cube Aug 20, 2025

Swiss firm Santhera Pharmaceuticals (SWX: SANN), a leader in innovative therapies for rare diseases, has...

Company Deals

Vivatides Therapeutics Completes Multi-Million Dollar Seed Financing to Advance Nucleic Acid Delivery Platform

Fineline Cube Aug 20, 2025

Biopharmaceutical company Vivatides Therapeutics has successfully completed a multi-million dollar seed round financing led by...

Policy / Regulatory

China Unveils Ten Measures to Boost Family Doctor Contract Services

Fineline Cube Aug 20, 2025

In a significant move to enhance the quality and accessibility of primary healthcare, the National...

Company Deals

Hunan FangSheng Pharmaceutical to Acquire JAK Inhibitor Patent Rights for RMB 80 Million

Fineline Cube Aug 20, 2025

Hunan FangSheng Pharmaceutical Co., Ltd. (SHA: 603998) announced today that it has reached an agreement...

Company Drug

Haihe Biopharma Seeks Japan Approval for Risovalisib in PIK3CA-Mutated Ovarian Cancer

Fineline Cube Aug 20, 2025

Haihe Biopharma Co., Ltd. has filed a market application with Japan’s Ministry of Health, Labour...

Company Deals

XtalPi Collaborates with Dong-A ST on AI-Driven Drug Discovery for Immunological Diseases

Fineline Cube Aug 20, 2025

Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228) and Korea’s leading pharmaceutical company, Dong-A...

Posts pagination

1 … 49 50 51 … 603

Recent updates

  • Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal
  • HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review
  • NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion
  • Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China
  • Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.